These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15751713)

  • 41. [Roncoleukin immunomodulation in pulmonary tuberculosis].
    Knoring BE; El'kin AV; Smirnov MN; Sakharova IIa; Basek TS
    Probl Tuberk; 1999; (5):26-9. PubMed ID: 10565213
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Interferon in combined treatment of patients with chronic inflammatory processes of the internal genitalia].
    Dubossarskaia ZM; Kuznetsov VP
    Akush Ginekol (Mosk); 1991 Dec; (12):38-40. PubMed ID: 1789345
    [No Abstract]   [Full Text] [Related]  

  • 43. [Immunological correction in progressive pulmonary tuberculosis].
    Maslennikov AA; Kamenev VF; Kolomiets VM
    Probl Tuberk Bolezn Legk; 2007; (9):30-3. PubMed ID: 18038603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Changes in the immune status parameters and their correction in various forms of tick-borne encephalitis].
    Krylova NV; Iakusheva SS; Borisevich VG; Leonova GN
    Antibiot Khimioter; 2001; 46(7):23-6. PubMed ID: 11697240
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Effect of treatment with glucocorticoids, pyrogenal and lidase on natural immunity in pulmonary tuberculosis patients].
    Mezhebovskiĭ VR
    Probl Tuberk; 1986; (2):34-8. PubMed ID: 3703841
    [No Abstract]   [Full Text] [Related]  

  • 46. [The combined use of corticosteroids and immunostimulators in the combination therapy of patients with tuberculosis of the lungs (methodologic recommendations].
    Averbakh MM; Chukanov VI; Khomenko IS; Gergert VIa; Naumov VN; Abramova ZP; Kolodiazhnaia NS; Eremeev VV; Titiukhina MM; Iusupova MM
    Probl Tuberk; 1992; (9-10):33-4. PubMed ID: 1461900
    [No Abstract]   [Full Text] [Related]  

  • 47. [Experimental substantiation of immunomodulating therapy with sodium nucleinate in tuberculosis].
    Cernuşenko EF; Ciumak AA
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1984; 33(2):143-50. PubMed ID: 6093221
    [No Abstract]   [Full Text] [Related]  

  • 48. [Effect of thymalin on the nonspecific resistance of pulmonary tuberculosis patients].
    Rybalko VV; Brazhenko NA; Khavinson VKh
    Voen Med Zh; 1986 May; (5):34-6. PubMed ID: 3755557
    [No Abstract]   [Full Text] [Related]  

  • 49. L-arginine and vitamin D: novel adjunctive immunotherapies in tuberculosis.
    Ralph AP; Kelly PM; Anstey NM
    Trends Microbiol; 2008 Jul; 16(7):336-44. PubMed ID: 18513971
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Effects of immunomodulating therapy on immune status and the disease course in patients with relapsing herpetic stomatitis].
    Rabinovich OF; Rabinovich IM; Pinegin BV; Razzhivina NV
    Stomatologiia (Mosk); 2004; 83(5):20-3. PubMed ID: 15477835
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [The effect of leukinferon on the activity of phagocytosing cells in human salmonellosis].
    Zueva VS; Spivak NIa; Fil'chakov IV; Kuznetsov VP; Bratus' EV
    Zh Mikrobiol Epidemiol Immunobiol; 1991 Sep; (9):21-5. PubMed ID: 1759515
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Interferon preparations in the complex treatment of bacterial infections].
    Kuznetsov VP; Beliaev DL; Babaiants AA; Tugutova I; Zueva VS; Volkova LB; Khusainov RM; Frolova IS; Zueva LA
    Antibiot Khimioter; 1989 Sep; 34(9):691-6. PubMed ID: 2610538
    [No Abstract]   [Full Text] [Related]  

  • 53. [Blood proteolytic systems in patients with pulmonary tuberculosis].
    Khudzik LB; Morozova TI
    Probl Tuberk; 1994; (5):56-8. PubMed ID: 7870735
    [No Abstract]   [Full Text] [Related]  

  • 54. Type I interferons as vaccine adjuvants against infectious diseases and cancer.
    Bracci L; La Sorsa V; Belardelli F; Proietti E
    Expert Rev Vaccines; 2008 Apr; 7(3):373-81. PubMed ID: 18393607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Interferon as an antineoplastic drug].
    Robak T
    Pol Tyg Lek; 1988 Jul; 43(28):899-902. PubMed ID: 3247258
    [No Abstract]   [Full Text] [Related]  

  • 56. [Some regularities of an immune response in patients with pulmonary tuberculosis and drug-resistant Mycobacterium strains].
    Sakharova IIa; Ariél' BM; Knoring BE; Skvortsova LA; Vasil'eva GIu; Vishnevskiĭ BI; Pogodaeva SS
    Probl Tuberk Bolezn Legk; 2008; (12):22-7. PubMed ID: 19230184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Effectiveness of Imudon in patients with acute and chronic inflammatory diseases of pharynx].
    Luchikhin LA; Malchenko OV
    Vestn Otorinolaringol; 2001; (3):62-4. PubMed ID: 11510054
    [No Abstract]   [Full Text] [Related]  

  • 58. [Clinicoimmunological features and treatment of acute intestinal infection of Proteus etiology].
    Iushchuk ND; Frolov VM; Peresadin NA
    Klin Med (Mosk); 1996; 74(4):67. PubMed ID: 8999164
    [No Abstract]   [Full Text] [Related]  

  • 59. Immune markers measured before treatment predict outcome of intensive phase tuberculosis therapy.
    Brahmbhatt S; Black GF; Carroll NM; Beyers N; Salker F; Kidd M; Lukey PT; Duncan K; van Helden P; Walzl G
    Clin Exp Immunol; 2006 Nov; 146(2):243-52. PubMed ID: 17034576
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The production of active forms of oxygen by neutrophils in volunteers receiving leukinferon and reaferon].
    Sirina EG; Tugutova IV; Zmyzgova AV; Iushchuk ND; Mesniankin AP
    Zh Mikrobiol Epidemiol Immunobiol; 1990 Apr; (4):93-7. PubMed ID: 2385996
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.